Home > Market Activity > Get Quotes > News > News Article

Harley-Davidson Inc.

Exchange: New York Stock Exchange | Oct 22, 2018, 11:06 AM EDT

$ 38.87 Change Down
-0.70 (-1.77%)

Day Low 38.27
Day High 39.52

Harley-Davidson (HOG) Expands Product Portfolio, Dealerships

On Jan 2, we issued an updated research report on Harley-Davidson, Inc. HOG.

The company has set a long-term plan to boost sales growth. In fact, Harley-Davidson has set a target of launching 100 new motorcycles by 2027. In 2017, the Milwaukee, WI-based company unveiled two motorcycles, the Road King Special and a more affordable Street Rod 750. Also, the company is developing its first electric motorcycle, Project LiveWire. All these efforts are aiding its revenue growth.

Also, Harley-Davidson is making concerted efforts to improve its international reach and anticipates an increase of 50% in yearly volume by 2027. In sync with this strategy, the company is adding new dealerships across the globe. The company aims to add 150-200 new dealerships internationally by 2020.

Harley-Davidson has a long-term growth rate of 8.5%. Over the past 60 days, the Zacks Consensus Estimate for Harley-Davidson’s quarterly estimates has gone up.

The company has outperformed the industry it belongs to in the last three months. Its shares have gained 6.7% against the industry’s loss of 5.5 %.

Harley-Davidson currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

A few other top-ranked automobile stocks in the same space are Continental AG CTTAY, Allison Transmission Holdings, Inc. ALSN and BorgWarner Inc. BWA, each carrying a Zacks Rank #2 (Buy).  

Continental AG has a long-term growth rate of 8.6%. The company’s shares have gained 39% in the past 12 months.

Allison Transmission has a long-term growth rate of 10%. The company’s shares have gained 28.4% in the past 12 months.

BorgWarner has a long-term growth rate of 8.6%. The company’s shares have gained 26.9% in the past 12 months.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.